NeuroGenetics Curriculum·intermediate·25 min

Genetic Causes of Cerebral Palsy

A modern genetics perspective on cerebral palsy — challenging the traditional view of CP as purely an acquired perinatal injury and examining the growing evidence that genetic variants, chromosomal abnormalities, and brain malformations underlie a substantial proportion of cases. Covers diagnostic approach, genotype-phenotype correlations, and counseling.

Tags: Neurogenetics

Learning Objectives

1.Describe the current understanding of genetic contributions to cerebral palsy and revise the traditional concept of CP as purely acquired
2.Identify clinical features that increase the likelihood of a genetic etiology in a child labeled with CP
3.List major genetic causes and chromosomal abnormalities that present with a CP phenotype
4.Explain why conditions such as dopa-responsive dystonia and GLUT1 deficiency are critical treatable mimics of CP
5.Select appropriate genetic tests for a child with suspected or confirmed CP

01Redefining Cerebral Palsy: Beyond Perinatal Injury

Cerebral palsy (CP) is clinically defined as a group of permanent disorders of movement and posture caused by non-progressive disturbances that occurred in the developing fetal or infant brain. Historically, CP was considered synonymous with perinatal hypoxic-ischemic injury. However, large epidemiological and genomic studies now demonstrate that genetic causes — including chromosomal abnormalities, pathogenic copy number variants, and single-gene disorders — account for approximately 20–30% of CP cases, and potentially more in cases without a clear perinatal etiology.

CP Motor Subtypes

Subtype	Motor Topography	Predominant Tone	MRI Correlates
Spastic (~80%)	Diplegia / hemiplegia / quadriplegia	Velocity-dependent ↑ tone	PVL (preterm diplegia); MCA infarct (hemiplegia); diffuse injury (quad)
Dyskinetic (~15%)	Trunk / limb / whole-body	Dystonia ± choreoathetosis	Bilateral BG/thalamic signal (term HIE); kernicterus → GP
Ataxic (~5%)	Trunk / appendicular	Cerebellar ataxia / hypotonia	Cerebellar hypoplasia; posterior fossa malformation
Mixed	Variable	Spasticity + dystonia most common	Reflects mixed mechanisms

GMFCS Levels I–V

Level	Functional Description	Mobility
I	Walks without limitations	Community ambulation; runs/jumps with speed & coordination limitations
II	Walks with limitations	Assistive device outdoors; limited stairs & uneven surfaces
III	Walks with hand-held device	Wheelchair for distances; some household ambulation
IV	Wheelchair-dependent	May achieve standing transfers; limited self-mobility
V	Transported in wheelchair	No independent mobility; head/trunk control limited

Clinical Pearl: GMFCS level is the strongest predictor of long-term ambulation. Genetic diagnosis does not change GMFCS but may redirect treatment strategy (e.g., DRD → levodopa instead of SDR).

Key Points

Modern definition: CP is a clinical syndrome (motor impairment + non-progressive brain abnormality) — not a specific diagnosis; etiology must be sought
Genetic contribution: ~14–31% of 'idiopathic' CP cases have identifiable genetic cause by chromosomal microarray + exome sequencing; genetic cause more common in term births without perinatal risk factors
CP mimics (treatable conditions misdiagnosed as CP): dopa-responsive dystonia (DYT-GCH1; see [[dystonia|Genetic Dystonias]] module), GLUT1 deficiency, AADC deficiency (DDC), glutaric aciduria type 1, biotinidase deficiency, arginase deficiency (ARG1) — critical to exclude before accepting CP label
Brain imaging in CP: MRI normal in 15–30% — higher genetic yield in these cases; periventricular leukomalacia (preterm injury), cortical dysplasia (genetic), vascular patterns (coagulopathy, COL4A1) all provide diagnostic clues
Clinical subtypes and genetic associations: spastic diplegia (periventricular leukomalacia most common — but also SPAST, PLP1 spastic paraplegia), dystonic CP (often treatable, DRD must be excluded), hemiplegic CP (focal cortical malformation, stroke, COL4A1)

02Chromosomal Abnormalities and CNVs in CP

Chromosomal abnormalities and copy number variants (CNVs) are identified in 8–15% of children with CP phenotype. These include classic chromosomal aneuploidies, sub-microscopic deletions and duplications detected by microarray, and uniparental disomy. Recognition of a chromosomal etiology reframes the diagnosis, provides recurrence risk information, and may identify additional health surveillance needs.

Key Points

Chromosomal microarray diagnostic yield in CP: ~7–11% when applied to children with CP phenotype regardless of MRI findings; highest yield in term-born children with no perinatal risk factor and normal/non-diagnostic MRI
17p13.3 deletions (LIS1/PAFAH1B1, YWHAE): Miller-Dieker syndrome — pachygyria/lissencephaly on MRI; most severe neurological impairment; facial features
15q11-13 duplication/Prader-Willi/Angelman: Angelman syndrome can present as 'CP-like' with ataxic gait, absent speech, seizures — SNRPN methylation testing is important
1p36 deletion syndrome: hypotonia, moderate-severe intellectual disability, seizures, cardiomyopathy — can present as CP phenotype; specific distinctive features
Xq28 MECP2 duplication: males with progressive spastic quadriplegia, severe intellectual disability, respiratory infections — clinically resembles CP; distinguished by progressive course and X-linked family history. Somatic mosaicism can also complicate CP phenotype interpretation (see the [[mosaicism|Mosaicism]] module)

03Monogenic Causes and CP Mimics

Single-gene variants can produce phenotypes that meet clinical criteria for CP — motor impairment present from infancy in the context of an apparently non-progressive course. At least 10 monogenic conditions are commonly misdiagnosed as CP: DRD (GCH1), HSP (SPG4+), AHC (ATP1A3), leukodystrophies, Rett (MECP2), ARG1 deficiency, GA1 (GCDH), NPC, mitochondrial disease, and spinal cord pathology. A levodopa trial is MANDATORY in any child with dystonia and a normal MRI — DRD response is dramatic within days, low risk, and potentially life-changing. ARG1 deficiency presents as progressive spastic diplegia with elevated plasma arginine and is a treatable urea cycle disorder. Progressive or regressive course rules out CP by definition and demands urgent metabolic and genomic workup.

CP Mimickers — 10 Conditions to Know

Disorder	Red Flag	Gene	Key Test
Dopa-responsive dystonia	Diurnal variation — worse PM, better AM	GCH1	Levodopa trial (MANDATORY)
Hereditary spastic paraplegia	Progressive spastic diplegia; multi-generational “CP”	SPG4 + >80 genes	Gene panel / WES
Alternating hemiplegia of childhood	Episodic hemiplegia alternating sides; onset <18 mo	ATP1A3	Gene sequencing
Leukodystrophies	Regression after plateau	Multiple	MRI white matter signal + WES
Rett syndrome	Regression 12–18 mo; hand stereotypies	MECP2	MECP2 sequencing
Arginase deficiency	Progressive spastic diplegia; ID	ARG1	Plasma arginine
Glutaric aciduria type 1	Macrocephaly + striatal injury after crisis	GCDH	Urine organic acids; newborn screen
Niemann-Pick C	VSGP + ataxia + cognitive decline + HSM	NPC1/NPC2	Oxysterols; filipin staining
Mitochondrial disease	Episodic decompensation; multi-system	Multiple	Lactate; Leigh pattern MRI
Spinal cord pathology	Progressive diplegia; bowel/bladder dysfunction	N/A	Spinal MRI

Levodopa Trial Protocol: Start 1–2 mg/kg/day divided TID, titrate over 2–4 weeks. DRD response: dramatic within days. Low risk, potentially life-changing. MANDATORY in dystonia + normal MRI.

Red Flag Rule: If “CP” is progressive or regressive — STOP. It is not CP. Rethink the diagnosis with metabolic screen + WES/WGS.

Key Points

DRD (GCH1): diurnal variation of dystonia (worse PM, better AM); normal MRI; levodopa trial MANDATORY — start 1-2 mg/kg/day TID, titrate over 2-4 weeks; dramatic response confirms diagnosis; low risk, potentially life-changing
HSP (SPG4 and >80 genes): progressive spastic diplegia mimicking CP; thin corpus callosum; AD inheritance — multi-generational 'CP' families are HSP until proven otherwise
AHC (ATP1A3): episodic hemiplegia alternating sides, onset <18 months; sleep resolves episodes; may develop fixed dystonia over time
ARG1 (arginase deficiency): progressive spastic diplegia with elevated plasma arginine — treatable UCD with protein restriction; hyperammonemia may be absent or subtle; must check plasma amino acids in any 'progressive CP'
GA1 (GCDH): macrocephaly + bilateral striatal injury after metabolic crisis; frontotemporal hypoplasia on MRI; identifiable on newborn screen; dietary lysine restriction prevents striatal crisis

04Genetic Workup for Cerebral Palsy

The genetic investigation of CP has evolved from a karyotype-and-wait approach to a comprehensive tiered evaluation combining brain MRI, metabolic screening, chromosomal microarray, and exome sequencing. The yield of genetic testing is highest in term-born children without clear perinatal hypoxic-ischemic injury, children with normal or non-lesional MRI, and children with additional features (distinctive features, family history, regression, movement disorder beyond motor impairment).

Etiological Workup by Scenario

Scenario	First-line Testing	Key Action
1. All CP	Brain MRI	Identifies cause in ~80%. Normal MRI = RED FLAG — pursue genetic/metabolic workup
2. Normal MRI / Unexplained	CMA + epilepsy panel or WES + metabolic screen	PAA, UOA, lactate, acylcarnitines
3. Dyskinetic / Dystonic + Normal MRI	Levodopa trial + CSF neurotransmitters	GCH1/TH genes + plasma arginine
4. Family Hx / Consanguinity / Distinctive Features	CMA → WES/WGS	Trio preferred for de novo detection
5. Progressive / Regression	Metabolic screen + WES/WGS urgently	STOP — reconsider CP diagnosis

Emerging: WGS as first-tier in some centers — detects SVs, repeat expansions, deep intronic variants; yield ~35–40%.

Key Points

Tier 1: Brain MRI (3T if possible, with DWI and T2/FLAIR); evaluate for lesion pattern (PVL, cortical malformation, vascular, normal); metabolic panel (plasma amino acids, urine organic acids, lactate, ammonia, acylcarnitines); SNRPN methylation if Angelman features; levodopa trial if any diurnal fluctuation or dystonia
Tier 2: Chromosomal microarray (SNP-based, for CNV and UPD); Fragile X if appropriate; specific targeted testing based on metabolic/clinical findings (e.g., GLUT1 if CSF:blood glucose low, SLC6A3 if parkinsonism-dystonia)
Tier 3: Exome sequencing (trio analysis — patient + both parents preferred for de novo detection); highest yield ~25–30% in carefully selected patients with 'idiopathic CP'
Features predicting high genetic yield: term birth, no HIE, normal MRI OR cortical malformation, family history of developmental delay/CP, additional features beyond motor (epilepsy, regression, movement disorder, distinctive features)
Whole-genome sequencing: emerging as first-tier in some centers; detects SVs and deep intronic variants missed by exome; may screen for some short tandem repeat disorders; diagnostic yield ~35–40% in selected pediatric neurogenetics populations

05Counseling and Management After Genetic Diagnosis

Identifying a genetic etiology in a child labeled with CP fundamentally changes the clinical trajectory — it provides a precise diagnosis, informs recurrence risk counseling for the family, directs surveillance for associated comorbidities, and increasingly identifies patients eligible for targeted therapies. Families should understand that a genetic diagnosis explains the cause without diminishing access to rehabilitation, educational, and therapeutic supports.

Treatment Reference

Medication	Mechanism	Indication	Pearls
Oral Baclofen	GABA-B agonist	First-line spasticity	Titrate slowly; never stop abruptly (withdrawal risk)
Trihexyphenidyl	Anticholinergic	Dystonia	Titrate over weeks; watch cognitive & autonomic side effects
Levodopa	DA precursor	Mandatory DRD trial	1–2 mg/kg/day TID; dramatic response = DRD confirmed
BoNT-A	NMJ blockade	Focal spasticity	Targeted muscles; repeat q3–6 mo; adjunct to therapy
ITB Pump	Intrathecal GABA-B	Severe; GMFCS III–V	Trial dose first; requires surgical implant & refills
SDR	Dorsal rhizotomy	Spastic diplegia GMFCS II–III	NOT for dystonia; requires intensive post-op PT

⚠ Baclofen Withdrawal — EMERGENCY: Fever + altered mental status + rigidity + seizures + autonomic instability = baclofen withdrawal. Treat with IV benzodiazepines. If ITB pump — call neurosurgery STAT for pump interrogation.

Key Points

Recurrence risk depends entirely on the genetic mechanism: de novo CNV or variant — <1% recurrence (germline mosaicism caveat); autosomal recessive — 25% per pregnancy; autosomal dominant variant inherited from affected parent — 50%; X-linked — depends on sex and carrier status
Identifying treatable causes changes prognosis: DRD responds dramatically to levodopa; GLUT1 improves on ketogenic diet; AADC deficiency responds to gene therapy; GA1 can be prevented with dietary lysine restriction; biotinidase deficiency resolves with biotin
Comorbidity surveillance by diagnosis: Down syndrome (thyroid, cardiac, sleep apnea); Angelman syndrome (epilepsy, scoliosis); MECP2 duplication (pulmonary hypertension, respiratory failure); SPG4 (urological symptoms, progressive course requiring active physiotherapy)
The CP label does not preclude genetic investigation: some clinicians are reluctant to pursue genetics after CP diagnosis, believing etiology is established; evidence shows 20–30% of labeled CP cases have genetic causes that matter for management and family planning
Variant of uncertain significance (VUS) counseling: ~20–30% of exome results yield VUS; distinguish VUS from pathogenic; review annually as databases grow; encourage research participation for data sharing

Quiz Questions

1. A 4-year-old child born at term without perinatal complications has been labeled with 'spastic diplegic cerebral palsy.' MRI is reported as normal. She has diurnal fluctuation of her tone — worse in the evening, better in the morning. The most important next step is:

A.Chromosomal microarray to identify a CNV causing spastic diplegia
B.Brain MRI at 3T with volumetric sequences — the normal MRI was likely a technical artifact
C.A therapeutic trial of levodopa/carbidopa to evaluate for dopa-responsive dystonia✓
D.Exome sequencing — this is likely a de novo SPAST variant causing hereditary spastic paraplegia

Diurnal fluctuation of tone — worse in the evening, dramatically improved in the morning — is the cardinal feature of dopa-responsive dystonia (DRD, GCH1 deficiency). DRD is one of the most important treatable mimics of cerebral palsy and should be excluded in any child with 'dystonic CP' or fluctuating tone before accepting the CP label. Response to low-dose levodopa is dramatic and sustained. Missing this diagnosis is clinically consequential.

2. A term-born child with moderate intellectual disability, absent speech, seizures, and a happy, social demeanor is initially labeled with CP. SNRPN methylation testing shows only the unmethylated (paternal) band present, with the methylated (maternal) band absent. This child most likely has:

A.MECP2 duplication syndrome — X-linked progressive spastic-intellectual disability
B.Angelman syndrome — maternal 15q11-13 deletion or UPD15 causing absent UBE3A expression✓
C.Prader-Willi syndrome — paternal 15q11-13 expression loss causing hypotonia and hyperphagia
D.Down syndrome — trisomy 21 presenting as spastic CP

Absent maternal (methylated) SNRPN band indicates Angelman syndrome — loss of the maternal 15q11-13 region, resulting in absent UBE3A expression (UBE3A is expressed only from the maternal allele in neurons). In SNRPN methylation testing, the methylated allele is maternal and the unmethylated allele is paternal. In Angelman syndrome (maternal deletion/UPD/IC defect), the maternal (methylated) band is absent, leaving only the paternal (unmethylated) band. Conversely, in Prader-Willi syndrome (paternal deletion), the paternal (unmethylated) band is absent, leaving only the maternal (methylated) band. Angelman syndrome frequently presents as CP: ataxic gait, absent/minimal speech, seizures, and intellectual disability. The characteristic happy, social affect and seizure pattern (with triphasic EEG delta activity) distinguish it.

3. Glutaric aciduria type 1 (GA1) can mimic CP. The mechanism of neurological injury in GA1 is:

A.Progressive accumulation of glutaric acid in white matter causing demyelination
B.Acute striatal necrosis triggered by febrile illness during a vulnerable period of development✓
C.Mitochondrial complex II inhibition causing basal ganglia infarction
D.Glutaric acid accumulation causing direct cortical neurotoxicity

In glutaric aciduria type 1 (GCDH gene deficiency), the typical neurological injury is acute bilateral striatal (caudate and putamen) necrosis that occurs during a febrile illness in the first 5 years of life. This 'striatal crisis' results in a dyskinetic-dystonic movement disorder that can be mistaken for dyskinetic CP. MRI shows bilateral striatal lesions + frontotemporal atrophy + macrocephaly. GA1 is detected on newborn screening, and dietary lysine restriction prevents striatal crisis — making early diagnosis critical.

4. Which clinical feature would most strongly support pursuing exome sequencing in a child labeled with CP?

A.Term birth, severe perinatal asphyxia, and MRI showing basal ganglia and thalamic injury
B.Preterm birth at 26 weeks with periventricular leukomalacia on MRI
C.Term birth, no perinatal risk factors, normal MRI, positive family history of early developmental delay, and additional features of movement disorder beyond motor impairment✓
D.Traumatic birth with subgaleal hemorrhage and subsequent spastic hemiplegia

The highest genetic diagnostic yield in CP investigations occurs in children with: term birth, absence of a clear perinatal event, normal or non-lesional MRI, and additional features beyond motor impairment (family history, epilepsy, intellectual disability, movement disorder, regression). In this group, exome sequencing (trio preferred) has a diagnostic yield of ~25–30%. Children with clear acquired causes (perinatal asphyxia, PVL, trauma) have much lower genetic yields.

5. After exome sequencing, a child with CP phenotype is found to have a de novo pathogenic variant in KIF1A. The recurrence risk for the parents' next pregnancy is approximately:

A.25% — this is autosomal recessive
B.50% — KIF1A is autosomal dominant with full penetrance
C.<1% — de novo pathogenic variants have very low recurrence risk (with germline mosaicism caveat of ~1–2%)✓
D.No increased risk — de novo variants cannot recur

A confirmed de novo pathogenic variant (present in the child but absent from both parents' blood DNA) has a very low recurrence risk — generally <1% for the next pregnancy, reflecting the low but non-zero risk of germline mosaicism in one parent. It is important to counsel families that recurrence is unlikely but not impossible, and that prenatal testing (CVS or amniocentesis) for the known variant is available. The risk to the proband's own future children (when applicable) is 50% for a fully penetrant autosomal dominant variant.